All In MedTech

FDA Clearance Tracker · P170002-S050

RHA Redensity® Eye Lido; RHA Redensity® Eye

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 12, 2026

Approved

Time to decision

256 days

Received Aug 29, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P170002-S050
Device name
RHA Redensity® Eye Lido; RHA Redensity® Eye
Applicant
Teoxane S.A.
Applicant location
Geneva
Received
Aug 29, 2025
Decided
May 12, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P170002

Device type

Device class
Class III

Every decision under product code LMH

FDA's approval statement

As written in FDA's record.

Approval for RHA Redensity® Eye Lido and RHA Redensity® Eye for expanding the indications to include injection into the sub-dermis and supraperiosteum for the correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults aged 22 years or older.

Source documents

Other decisions for Teoxane S.A.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.